董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Frank Witney | -- | Director | -- | 27.43万美元 | 57.30 | 2026-03-09 |
| Eli Casdin | -- | Director | -- | 26.13万美元 | 9389.12 | 2026-03-09 |
| Fenel M. Eloi | -- | Director | -- | 26.93万美元 | 51.01 | 2026-03-09 |
| Tom Carey | -- | Chairperson of the Board and Director | -- | 35.93万美元 | 79.30 | 2026-03-09 |
| Kathy Hibbs | -- | Director | -- | 26.43万美元 | 57.00 | 2026-03-09 |
| Troy Cox | -- | Director | -- | 26.63万美元 | 202.79 | 2026-03-09 |
| Michael Egholm | 男 | President,Chief Executive Officer and Director | 63 | 882.35万美元 | 854.74 | 2026-03-09 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sean Mackay | 男 | Chief Business Officer | 43 | 169.25万美元 | 87.67 | 2026-03-09 |
| Alex Kim | 男 | Chief Financial Officer | -- | 400.52万美元 | 331.56 | 2026-03-09 |
| Michael Egholm | 男 | President,Chief Executive Officer and Director | 63 | 882.35万美元 | 854.74 | 2026-03-09 |
董事简历
中英对照 | 中文 | 英文- Frank Witney
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Eli Casdin
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Fenel M. Eloi
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Tom Carey
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Kathy Hibbs
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Troy Cox
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Michael Egholm
-
Michael Egholm， 他是博士。他于2010年6月被任命为首席技术官。加入美国颇尔之前，他担任 454 生命科学公司（罗氏应用科学卓越中心）的各种职务，包括研究和开发副总裁， 分子生物学的副总裁，以及首席技术官（从2008年到2010年）。
Michael Egholm,has served as a member of our board of directors since 2018. Dr. Egholm served as the Chief Technology Officer of Danaher Life Sciences, the life sciences arm of Danaher Corporation, a global science and technology company, from 2017 to 2021. Prior to that, he served as President, Biopharmaceuticals at Pall Corporation, a global supplier of filtration, separations and purification products, from 2014 to 2017 and as their Chief Technology Officer from 2010 to 2014. Dr. Egholm completed his Ph.D. and Master’s degree in Chemistry at the University of Copenhagen. - Michael Egholm， 他是博士。他于2010年6月被任命为首席技术官。加入美国颇尔之前，他担任 454 生命科学公司（罗氏应用科学卓越中心）的各种职务，包括研究和开发副总裁， 分子生物学的副总裁，以及首席技术官（从2008年到2010年）。
- Michael Egholm,has served as a member of our board of directors since 2018. Dr. Egholm served as the Chief Technology Officer of Danaher Life Sciences, the life sciences arm of Danaher Corporation, a global science and technology company, from 2017 to 2021. Prior to that, he served as President, Biopharmaceuticals at Pall Corporation, a global supplier of filtration, separations and purification products, from 2014 to 2017 and as their Chief Technology Officer from 2010 to 2014. Dr. Egholm completed his Ph.D. and Master’s degree in Chemistry at the University of Copenhagen.
高管简历
中英对照 | 中文 | 英文- Sean Mackay
Sean Mackay，我们的联合创始人，自2014年以来担任我们的首席执行官和董事会成员。Mackay先生还担任生物技术公司ABBRATECH的董事会成员。在此之前，Mackay先生在Lazard工作，并为多个行业的交易提供建议，帮助生命科学和医疗设备公司管理和重新配置其资本结构，以实现各种运营目标。此外，Mackay先生是Kleiner Perkins孵化的LifeSquare的一部分，该公司旨在通过共享基本的医疗保健信息来连接患者，付款人和提供者。在他的整个职业生涯中，Mackay先生一直专注于为公司提供建议和建立能够通过突破性技术改善医疗保健生态系统的公司。Mackay先生与人合著了以免疫学为中心的出版物，并且是单细胞产品多项专利的发明人。
Sean Mackay,our co-founder, has served as our Chief Executive Officer and as a member of our board of directors since 2014. Mr. Mackay also serves on the board of AbbraTech, a biotechnology company. Previously, Mr. Mackay worked at Lazard, and advised on a number of transactions across industries, helping life sciences and medical device companies manage and reconfigure their capital structures to pursue various operational goals. Additionally, Mr. Mackay was part of Kleiner Perkins-incubated Lifesquare, which aimed to connect patients, payers, and providers through sharing essential healthcare information. Throughout his career, Mr. Mackay has focused on advising and building companies that can improve the healthcare ecosystem with breakthrough technology. Mr. Mackay has co-authored publications centered around immunology and is an inventor on various patents for single cell products.- Sean Mackay，我们的联合创始人，自2014年以来担任我们的首席执行官和董事会成员。Mackay先生还担任生物技术公司ABBRATECH的董事会成员。在此之前，Mackay先生在Lazard工作，并为多个行业的交易提供建议，帮助生命科学和医疗设备公司管理和重新配置其资本结构，以实现各种运营目标。此外，Mackay先生是Kleiner Perkins孵化的LifeSquare的一部分，该公司旨在通过共享基本的医疗保健信息来连接患者，付款人和提供者。在他的整个职业生涯中，Mackay先生一直专注于为公司提供建议和建立能够通过突破性技术改善医疗保健生态系统的公司。Mackay先生与人合著了以免疫学为中心的出版物，并且是单细胞产品多项专利的发明人。
- Sean Mackay,our co-founder, has served as our Chief Executive Officer and as a member of our board of directors since 2014. Mr. Mackay also serves on the board of AbbraTech, a biotechnology company. Previously, Mr. Mackay worked at Lazard, and advised on a number of transactions across industries, helping life sciences and medical device companies manage and reconfigure their capital structures to pursue various operational goals. Additionally, Mr. Mackay was part of Kleiner Perkins-incubated Lifesquare, which aimed to connect patients, payers, and providers through sharing essential healthcare information. Throughout his career, Mr. Mackay has focused on advising and building companies that can improve the healthcare ecosystem with breakthrough technology. Mr. Mackay has co-authored publications centered around immunology and is an inventor on various patents for single cell products.
- Alex Kim
Alex Kim于2022年4月4日加入公司担任首席运营官，自2024年11月11日起担任首席财务官，此前自2024年9月1日起担任临时首席财务官。在加入公司之前，Kim先生自2021年10月起担任Standard BioTools，LLC的首席商务官。此前，他曾于2015年10月至2021年5月在Milliken & Company（“Milliken”）担任多个职务，包括2019年6月至2021年5月担任Milliken医疗保健部门执行副总裁兼总裁，2017年4月至2019年6月担任Growth Ventures Group执行副总裁，2015年10月至2019年6月担任企业战略和企业发展执行副总裁。在此之前，Kim先生曾在丹纳赫公司的颇尔、水质集团和Motion集团担任过各种领导职务。Kim先生获得了斯坦福大学商学院的工商管理硕士学位、匹兹堡大学的机械工程硕士学位和卡内基梅隆大学的机械工程学士学位。
Alex Kim joined the Company as Chief Operating Officer on April 4, 2022 and has served as Chief Financial Officer since November 11, 2024, after previously serving as Interim Chief Financial Officer since September 1, 2024. Prior to joining the Company, Mr. Kim served as Chief Business Officer of Standard BioTools, LLC since October 2021. Previously, he served in various roles at Milliken & Company ("Milliken") from October 2015 to May 2021, including Executive Vice President and President of the Healthcare Division of Milliken from June 2019 to May 2021, Executive Vice President of the Growth Ventures Group from April 2017 to June 2019, and as Executive Vice President of Corporate Strategy and Corporate Development from October 2015 to June 2019. Prior to that, Mr. Kim served in various leadership roles at the Pall Corporation, the Water Quality Group, and the Motion Group at the Danaher Corporation. Mr. Kim received an M.B.A. from the Stanford Graduate School of Business, an M.S. in Mechanical Engineering from the University of Pittsburgh, and a B.S. in Mechanical Engineering from Carnegie Mellon University.- Alex Kim于2022年4月4日加入公司担任首席运营官，自2024年11月11日起担任首席财务官，此前自2024年9月1日起担任临时首席财务官。在加入公司之前，Kim先生自2021年10月起担任Standard BioTools，LLC的首席商务官。此前，他曾于2015年10月至2021年5月在Milliken & Company（“Milliken”）担任多个职务，包括2019年6月至2021年5月担任Milliken医疗保健部门执行副总裁兼总裁，2017年4月至2019年6月担任Growth Ventures Group执行副总裁，2015年10月至2019年6月担任企业战略和企业发展执行副总裁。在此之前，Kim先生曾在丹纳赫公司的颇尔、水质集团和Motion集团担任过各种领导职务。Kim先生获得了斯坦福大学商学院的工商管理硕士学位、匹兹堡大学的机械工程硕士学位和卡内基梅隆大学的机械工程学士学位。
- Alex Kim joined the Company as Chief Operating Officer on April 4, 2022 and has served as Chief Financial Officer since November 11, 2024, after previously serving as Interim Chief Financial Officer since September 1, 2024. Prior to joining the Company, Mr. Kim served as Chief Business Officer of Standard BioTools, LLC since October 2021. Previously, he served in various roles at Milliken & Company ("Milliken") from October 2015 to May 2021, including Executive Vice President and President of the Healthcare Division of Milliken from June 2019 to May 2021, Executive Vice President of the Growth Ventures Group from April 2017 to June 2019, and as Executive Vice President of Corporate Strategy and Corporate Development from October 2015 to June 2019. Prior to that, Mr. Kim served in various leadership roles at the Pall Corporation, the Water Quality Group, and the Motion Group at the Danaher Corporation. Mr. Kim received an M.B.A. from the Stanford Graduate School of Business, an M.S. in Mechanical Engineering from the University of Pittsburgh, and a B.S. in Mechanical Engineering from Carnegie Mellon University.
- Michael Egholm
Michael Egholm， 他是博士。他于2010年6月被任命为首席技术官。加入美国颇尔之前，他担任 454 生命科学公司（罗氏应用科学卓越中心）的各种职务，包括研究和开发副总裁， 分子生物学的副总裁，以及首席技术官（从2008年到2010年）。
Michael Egholm,has served as a member of our board of directors since 2018. Dr. Egholm served as the Chief Technology Officer of Danaher Life Sciences, the life sciences arm of Danaher Corporation, a global science and technology company, from 2017 to 2021. Prior to that, he served as President, Biopharmaceuticals at Pall Corporation, a global supplier of filtration, separations and purification products, from 2014 to 2017 and as their Chief Technology Officer from 2010 to 2014. Dr. Egholm completed his Ph.D. and Master’s degree in Chemistry at the University of Copenhagen.- Michael Egholm， 他是博士。他于2010年6月被任命为首席技术官。加入美国颇尔之前，他担任 454 生命科学公司（罗氏应用科学卓越中心）的各种职务，包括研究和开发副总裁， 分子生物学的副总裁，以及首席技术官（从2008年到2010年）。
- Michael Egholm,has served as a member of our board of directors since 2018. Dr. Egholm served as the Chief Technology Officer of Danaher Life Sciences, the life sciences arm of Danaher Corporation, a global science and technology company, from 2017 to 2021. Prior to that, he served as President, Biopharmaceuticals at Pall Corporation, a global supplier of filtration, separations and purification products, from 2014 to 2017 and as their Chief Technology Officer from 2010 to 2014. Dr. Egholm completed his Ph.D. and Master’s degree in Chemistry at the University of Copenhagen.